Items Tagged ‘urothelial carcinoma’

June 8th, 2016

Tecentriq® Approved for Bladder Cancer

By

The United States Food and Drug Administration (FDA) has approved Tecentriq (atezolizumab) for the treatment of bladder cancer. Atezolizumab is an immunotherapy agent referred to as a PD-1/PD-L1 inhibitor, and is the first agent in this class to be approved for the treatment of bladder cancer. Urothelial carcinoma (formerly known as transitional cell carcinoma) is […]

View full entry

Tags: atezolizumab, Bladder Cancer, inhibitor, News, PD-1, PD-L1, Stage IV/Metastatic Bladder Cancer, Tecentriq, urothelial carcinoma


January 21st, 2016

Atezolizumab Provides Long-Lasting Anti-Cancer Responses in Advanced Bladder Cancer

By

The immunotherapeutic agent, atezolizumab, which is still in investigative stages, provides high rates of anti-cancer responses among patients with advanced bladder cancer. These results were recently presented at the 2016 Genitourinary Cancers Symposium of the American Society of Clinical Oncology (ASCO GU). Urothelial carcinoma (formerly known as transitional cell carcinoma) is a cancer involving parts […]

View full entry

Tags: atezolizumab, Bladder Cancer, News, urothelial carcinoma